ArticleFrontiers in cellular and infection microbiology2025
Limitations of human t-lymphotropic virus type 1 antibody testing in hospitals of endemic regions in China.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to evaluate the sensitivity and specificity of human T-lymphotropic virus type 1 (HTLV-1) antibody testing within hospitals located in HTLV-1 endemic areas of China. Method: We performed a retrospective analysis of the clinical records and laboratory results for 1,147 patients who underwent HTLV-1 antibody testing using the Wantai HTLV-1 antibody detection kit and Polymerase Chain Reaction (PCR) testing for HTLV-1 nucleic acids, at Fujian Medical University Union Hospital between 2017 and 2023. Result: The study population comprised 674 males (58.8%) and 473 females (41.2%), with an age distribution ranging from 7 to 86 years, and a median age of 50 years. Of the patients, 81 (7.1%) tested positive for HTLV-1 antibodies, including 39 males and 42 females. Predominantly, these positive cases were identified within the hematology department (93.8%). The cases originated from several high-prevalence coastal regions in Fujian province, such as Pingtan Island, Fuqing, Changle, Lianjiang, Fuan, Shouning, Xiapu, Zhouning, Fuding, Jiaocheng, Xiuyu, and Licheng. According to current standards for interpreting positive results, only 79.6% of patients with adult T-cell leukemia/lymphoma (ATLL) confirmed by HTLV-1 nucleic acid testing presented positive antibody results. Comparison of HTLV-1 antibody and nucleic acid test results revealed that the antibody test possessed a sensitivity of 63.0% and a specificity of 94.8%. A receiver operating characteristic (ROC) curve analysis determined that a threshold of 0.335 signal-to-cutoff (S/CO) was optimal for classifying positive antibody test results, yielding a sensitivity of 86.3% and a specificity of 94.4%. Conclusion: The Wantai HTLV-1 antibody test kit, when utilized in hospitals within endemic regions, exhibits a high level of specificity. However, its sensitivity is found to be lacking when evaluated against the current standards for the interpretation of positive results. For patients with a high clinical suspicion of HTLV-1 infection-related diseases, it is crucial to conduct testing of HTLV-1 antibodies and nucleic acids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.